TY - CHAP M1 - Book, Section TI - The Goodman & Gilman Year in Review: 2017 New and Noteworthy FDA Approvals A1 - Murri, PharmD, MBA, Nelda A2 - Brunton, Laurence L. A2 - Hilal-Dandan, Randa A2 - Knollmann, Björn C. PY - 2017 T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e AB - In 2017 the U.S. Food and Drug Administration (FDA) approved 40 new small molecule drugs and granted 48 noteworthy biologic licenses. Among the 40 small molecules are two previously unapproved marketed drugs: calcium gluconate injection for symptomatic hypocalcemia (original approval 1941)1 and ascorbic acid injection (Ascor) for the short-term treatment of scurvy (initial approval 1947).2 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1179320477 ER -